STC-1010
Unresectable metastatic Microsatellite Stable (MSS) Colorectal Cancer (1L)
Phase 1/2Active
Key Facts
Indication
Unresectable metastatic Microsatellite Stable (MSS) Colorectal Cancer (1L)
Phase
Phase 1/2
Status
Active
Company
About Brenus Pharma
Brenus Pharma is a privately held, clinical-stage biotech founded in 2020 in Lyon, France. The company has developed a novel platform that creates 'ghost cell' immunotherapies designed to expose the broadest panel of cancer-associated antigens to the immune system, aiming to overcome the limitations of current immunotherapies in solid tumors. With €30M in strategic funding, Brenus is advancing its lead candidate, STC-1010, into Phase I/II trials for metastatic colorectal cancer, targeting a significant patient population with limited options. The company is led by a seasoned team with deep experience in oncology, drug development, and entrepreneurship.
View full company profile